Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
// Martina Di Modica 1, * , Lucia Sfondrini 2, * , Viola Regondi 1 , Stefania Varchetta 3 , Barbara Oliviero 3 , Gabriella Mariani 4 , Giulia Valeria Bianchi 4 , Daniele Generali 5 , Andrea Balsari 1, 2 , Tiziana Triulzi 1, * , Elda Tagliabue 1, * 1 Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy 2 Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy 3 Department of Infectious Diseases, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy 4 Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy 5 Dipartimento di Terapia Molecolare e Farmacogenomica, Istituti Ospitalieri di Cremona, Cremona, Italy * These authors have contributed equally to this work Correspondence to: Elda Tagliabue, e-mail: elda.tagliabue@istitutotumori.mi.it Keywords: breast cancer, docetaxel, ADCC, NK cell, NKG2D Received: October 28, 2015 Accepted: November 09, 2015 Published: November 21, 2015 ABSTRACT Recent clinical data indicate a synergistic therapeutic effect between trastuzumab and taxanes in neoadjuvantly treated HER2-positive breast cancer (BC) patients. In HER2+ BC experimental models and patients, we investigated whether this synergy depends on the ability of drug-induced stress to improve NK cell effectiveness and thus trastuzumab-mediated ADCC. HER2+ BC cell lines BT474 and MDAMB361 treated with docetaxel showed up-modulation of NK activator ligands both in vitro and in vivo , accompanied by a 15–40% increase in in vitro trastuzumab-mediated ADCC; antibodies blocking the NKG2D receptor significantly reduced this enhancement. NKG2D receptor expression was increased by docetaxel treatment in circulating and splenic NK cells from mice xenografted with tumor cells, an increase related to expansion of the CD11b + Ly6G + cell population. Accordingly, NK cells derived from HER2+ BC patients after treatment with taxane-containing therapy expressed higher levels of NKG2D receptor than before treatment. Moreover, plasma obtained from these patients recapitulated the modulation of NKG2D on healthy donors’ NK cells, improving their trastuzumab-mediated activity in vitro . This enhancement occurred mainly using plasma from patients with low NKG2D basal expression. Our results indicate that taxanes increase tumor susceptibility to ADCC by acting on tumor and NK cells, and suggest that taxanes concomitantly administered with trastuzumab could maximize the antibody effect, especially in patients with low basal immune effector cytotoxic activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Innate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
Gasser, S., Orsulic, S., Brown, E. J., & Raulet, D. H. (2005) · Nature · doi:10.1038/nature03884 · Cited by 1,308 · cited 1×
“It binds multiple ligands, including MHC class I chain-related A (MICA), MICB and several UL-16 binding proteins (ULBPs), which are induced after cellular stress [12] and are the most common ligands for NK cell receptors in breast carcinomas together with DNAM-1 ligands [13].”
BackgroundThe therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577
Gennari, R., Menard, S., Fagnoni, F., Ponchio, L., Scelsi, M., Tagliabue, E., Castiglioni, F., Villani, L., Magalotti, C., Gibelli, N., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0225 · Cited by 516
Self-citationKodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0733 · Cited by 500 · cited 1×
“Myeloid cells were purified from total splenocytes using biotinylated anti-GR1 antibody (Miltenyi Biotec, San Diego, CA, USA) as described [38].”
MethodStagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496 · cited 1×
“Activated NK cells are known to shape the adaptive immune response [32;33], described to be crucial for the complete eradication of BC upon trastuzumab treatment both in preclinical [34;35] and clinical samples [36;37].”
BackgroundImmune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes
Tsavaris, N., Kosmas, C., Vadiaka, M., Kanelopoulos, P., & Boulamatsis, D. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600347 · Cited by 343 · cited 1×
“Moreover, the selective expansion of CD11b+Ly6G+and the increase in NKG2D expression on NK cells in our models upon docetaxel treatment is consistent with the elevation of granulocytic myeloid cells after chemotherapy in patients [22], and with the increase in GM-CSF and IL6 production, that supports myeloid cell expa…”
Result
Cited by
Le Noci, V., Guglielmetti, S., Arioli, S., Camisaschi, C., Bianchi, F., Sommariva, M., Storti, C., Triulzi, T., Castelli, C., Balsari, A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.090 · Cited by 270
Self-citationEarly immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
Triulzi, T., Regondi, V., De Cecco, L., Cappelletti, M. R., Di Modica, M., Paolini, B., Lollini, P. L., Di Cosimo, S., Sfondrini, L., Generali, D., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0318-0 · Cited by 94
Self-citationThe Potential of Combining Tubulin-Targeting Anticancer Therapeutics and Immune Therapy
Fong, A., Durkin, A., & Lee, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030586 · Cited by 50
Natural Killer Cell Immunotherapy for Osteosarcoma
Tullius, B. P., Setty, B. A., & Lee, D. A. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43032-0_12 · Cited by 22
Metadata
- Authors
- Di Modica, M., Sfondrini, L., Regondi, V., Varchetta, S., Oliviero, B., Mariani, G., Bianchi, G. V., Generali, D., Balsari, A., Triulzi, T., & Tagliabue, E.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-11-21
- Volume
- 7
- Issue
- 1
- Pages
- 255-265
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2278665679
- Cited by
- 47
- References
- 7
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.